Hypothesis

Partial reprogramming with Yamanaka factors improves epigenetic age and tissue function but triggers a trade‑off that diminishes long‑term stem cell resilience (4). We propose that concurrent inhibition of mTORC1 with rapamycin preserves stem cell quiescence, thereby uncoupling short‑term repair gains from long‑term stem cell exhaustion and yielding a net lifespan extension.

Mechanistic Rationale

1. Epigenetic reset vs. stem cell stress – Transient expression of Oct4, Sox2, Klf4, c‑Myc (OSKM) drives chromatin remodeling that mimics youthful epigenetic states (2). This process, however, elevates proliferative signaling and mTOR activity, pushing stem cells out of quiescence and accelerating their attrition (4).
2. mTORC1 as the trade‑off mediator – Hyperactive mTORC1 promotes protein synthesis and senescence‑associated secretory phenotype, eroding the regenerative reserve of stem cell pools. Rapamycin, an allosteric mTORC1 inhibitor, restores a balanced anabolic‑catabolic state, enhances autophagy, and supports stem cell maintenance without blocking the beneficial epigenetic remodeling.
3. Predicted outcome – Mice receiving cyclic OSKM expression plus low‑dose rapamycin will show (a) comparable epigenetic clock reversal to OSKM alone, (b) improved tissue histology, and (c) a significant increase in median and maximal lifespan relative to OSKM‑only controls.

Experimental Design

• Groups (n=30 per group, both sexes):
  1. Vehicle control
  2. OSKM induction (doxycycline‑inducible, 2 days/week)
  3. Rapamycin alone (14 ppm in chow)
  4. OSKM + rapamycin (same OSKM schedule + rapamycin)
• Measurements:
  • Epigenetic clocks (e.g., Horvath mouse clock) at 3, 6, 12 months (1)
  • Tissue functional assays (grip strength, treadmill endurance, hepatic glycogen)
  • Stem cell compartment analyses (flow cytometry for LSK cells, competitive repopulation assays)
  • Survival monitoring until natural death.
• Falsification criteria: If the OSKM + rapamycin group does not exhibit a statistically significant lifespan increase over the OSKM‑only group (hazard ratio ≥ 0.9, p > 0.05), the hypothesis is refuted. Conversely, a lifespan extension without loss of epigenetic reversal or tissue function supports the hypothesis.

Broader Implications

Confirming that mTOR inhibition mitigates the stem‑cell resilience trade‑off would reframe rejuvenation strategies: biomarker reversal alone is insufficient; preserving stem cell quiescence is essential for translating clock changes into genuine longevity gains. This approach also offers a pragmatic path toward human trials, as rapamycin's safety profile is well established in aging cohorts.